Definitely a bit riding on the upcoming webinar.
If not mistaken, based on comments at the previous webinar, the pulse should (or soon) be in the hands of existing CDX partners, gathering data ahead for the small initial release. Before the progressively larger subsequent releases. Hopefully get some insight as to the progress on that front.
What would really help though is good news on the financial front. Evidence that cash burn is at an ‘acceptable’ level and any signs of pre-sales/revenue supporting a turnaround (although this may be a little early still). Given the small/soft launch not expecting huge numbers, rather proof of product and marketability.
Certainly plenty of arguments this company could go either way.
Add to My Watchlist
What is My Watchlist?
